Quantum-Si Incorporated ((QSI)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Quantum-Si earnings call balanced cautious optimism with clear execution risk as management highlighted major technical progress on its Proteus protein sequencing platform while acknowledging minimal near-term revenue. Executives stressed that the technology is now materially de-risked and funded into 2028, but investors will need patience as the company burns cash to convert scientific momentum into commercial traction.
Proteus Platform Achieves End-to-End Sequencing
Quantum-Si reported a key milestone with successful sequencing on fully integrated Proteus instruments, covering everything from reagent prep through data analysis in one automated workflow. Management framed this as a fundamental proof point that validates the core technology ahead of commercial launch and reduces technical risk on the next-generation platform.
Expanded Amino Acid Detection Capabilities
The company has increased the number of amino acids detected by its internal developmental kit from 15 in December 2025 to 17 by April or May 2026. Leadership expressed confidence that Proteus will reach 18 amino acids at launch and demonstrate all 20 during 2026, positioning the platform for broader protein sequencing applications.
Longer Read Lengths and Higher Throughput vs. Platinum
Customer prototype testing showed Proteus delivering roughly double the average peptide read length compared with the existing Platinum system. The platform also produced a much higher number of reads thanks to denser chip features, which management said should translate into more sequence-level information per protein and a stronger competitive profile.
Advancing Post-Translational Modification Detection
Quantum-Si highlighted significant progress on detecting post-translational modifications using kinetic signatures interpreted by AI-driven analysis. Executives described this as a universal sequencing chemistry approach that could extend beyond current affinity-based or mass spectrometry tools and open new research and clinical application avenues.
Roadshow, Publications, and Early Market Engagement
The company’s Proteus roadshow, launched in April, is drawing strong early interest, with one event attracting 35 attendees versus 25 registrations. Management also pointed to three customer manuscripts, five posters, and a podium presentation so far in 2026 as signs that awareness is building across academic, clinical, biopharma, and government markets.
Cash Runway Into 2028 Supports Development
Quantum-Si ended the first quarter with $190.4 million in cash, cash equivalents, and marketable securities, reiterating a cash runway into 2028. For 2026, the company guided to roughly $1 million in revenue, adjusted operating expenses of $98 million or less, and total cash usage of $93 million or less, supporting ongoing Proteus development and launch activities.
Expense Discipline Amid Heavy Investment
GAAP operating expenses fell to $24.1 million from $25.6 million year over year, while adjusted operating expenses dipped to $21.4 million from $22.9 million. Management said these declines reflect tighter spending on SG&A while concentrating resources on Proteus R&D, even as overall investment remains substantial.
Board Buying Underscores Insider Conviction
Executives characterized recent insider Form 4 activity as largely routine and tax-related but emphasized that two board members bought 600,000 shares in open market transactions. The company presented these purchases as a sign of board-level confidence in the Proteus strategy and long-term value creation potential.
Minimal Near-Term Revenue and Slow Top-Line Build
Quantum-Si generated just $258,000 of revenue in the first quarter, mainly from consumables used by its installed base. Management reiterated that 2026 revenue should be about $1 million, signaling very limited near-term growth as customers largely wait for Proteus availability before committing to larger spending.
Growth Hinges on Successful Proteus Launch
The company framed 2026 as a transition year in which revenue will lean on consumables and modest capital placements tied to upgrade credits. Executives were clear that meaningful revenue acceleration depends on a timely Proteus launch and broad customer adoption, making commercial execution the central driver of future growth.
High Ongoing R&D and Commercialization Spend
Despite modest cuts, Quantum-Si still plans up to $98 million in adjusted operating expenses and as much as $93 million of cash usage in 2026. Management said R&D intensity will remain high until after Proteus launches, when they expect to gradually reduce development spending and shift focus to scaling commercialization.
Lower Interest Income Reduces Non-Operating Cushion
Dividend and interest income fell to $1.9 million from $2.5 million year over year, reflecting lower rates and changes in invested balances. That drop modestly reduces the non-operating income buffer that had helped offset operating losses, making underlying operating performance more critical over time.
Customer Conversion and Scale-Up Risks Remain
Management acknowledged they cannot yet predict how many customers will switch from Platinum to Proteus or at what pace, with early-access deployments limited to a small number of sites. They also noted ongoing work to optimize instrument assembly and manage long-lead components, underscoring that manufacturing and scaling remain key execution risks.
Guidance Points to a Patience-Tested Transition Year
The company reaffirmed 2026 as a transition year with revenue of about $1 million, adjusted operating expenses capped at $98 million, and cash usage capped at $93 million, supported by $190.4 million in liquidity at quarter-end. Operationally, management aims to complete manufacturing scale-up, seed a handful of early-access sites by summer, expand sample evaluations as more internal Proteus instruments come online, and achieve stepwise gains toward detecting all 20 amino acids by 2027.
Quantum-Si’s latest call painted a picture of a company that has substantially de-risked its core technology while still standing at the starting line commercially. For investors, the story is now less about whether Proteus will work and more about how quickly management can scale manufacturing, convert interest into orders, and manage cash burn on the road from technical breakthrough to revenue growth.